Migea (Tolfenamic Acid)

Tolfenamic Acid, the active ingredient in Migea, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral formulation for oral use. It is used to relieve mild to moderate pain and inflammation in conditions such as rheumatoid arthritis, osteoarthritis, and musculoskeletal disorders.

GNH USA supplies Migea as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Migea (tolfenamic acid) is employed within the NSAID class to manage inflammatory and painful musculoskeletal conditions.

- Rheumatoid arthritis: reduces joint inflammation and pain, improving mobility. - Osteoarthritis: alleviates cartilage‑related discomfort and stiffness. - Musculoskeletal inflammation: diminishes swelling and soreness in muscles, tendons, and ligaments. - Mild to moderate pain: provides analgesic relief for acute or chronic pain episodes.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia - Nausea or vomiting - Headache - Dizziness - Mild skin rash - Elevated liver enzymes

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Severe hepatic injury - Acute renal impairment - Anaphylactic or severe hypersensitivity reactions - Blood dyscrasias such as agranulocytosis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before prescribing Migea, clinicians should consider several safety aspects.

- Assess gastrointestinal risk: evaluate history of ulcers or bleeding. - Monitor renal function: check creatinine and urine output regularly. - Evaluate hepatic status: perform liver function tests as needed. - Use caution in cardiovascular disease: NSAIDs may increase blood pressure. - Avoid in known hypersensitivity to tolfenamic acid or other NSAIDs. - Store at below 25°C: keep in the original pack, protect from moisture.

Tolfenamic acid can affect the activity of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - ACE inhibitors or diuretics: potential reduction in renal function.

Moderate Interactions (Monitor Closely): - Corticosteroids: heightened ulcer risk. - Methotrexate: possible increased toxicity. - Selective serotonin reuptake inhibitors (SSRIs): enhanced bleeding tendency.